Trials / Recruiting
RecruitingNCT05466643
A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus
A Multicenter, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of DWP16001 as add-on Therapy to Drug A, With or Without Antihyperglycemic Drugs, in Patients With Type 2 Diabetes Mellitus
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, randomized, placebo-controlled clinical trial, double-blind, parallel-group
Detailed description
Phase 3 study in patients with T2DM, who have inadequate glycemic control on Drug A alone or Drug A in combination with antihyperglycemic drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DWP16001 0.3mg | 1 tablet, Orally, Once daily single dose |
| DRUG | DWP16001 Placebo | 1 tablet, Orally, Once daily single dose |
Timeline
- Start date
- 2023-03-17
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
- First posted
- 2022-07-20
- Last updated
- 2024-04-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05466643. Inclusion in this directory is not an endorsement.